STOCK TITAN

[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Roivant Sciences (ROIV) – Form 4 filing (30 Jul 2025)

CFO Richard Pulik reported an automatic disposition of 1,919 common shares on 28 Jul 2025 at an implied price of $11.35. The transaction is coded “F”, indicating the issuer withheld shares to cover taxes due upon the vesting of previously granted restricted stock units (RSUs); no open-market sale occurred. After the net-settlement, Pulik retains 397,553 shares, so the shares surrendered equal roughly 0.5 % of his post-transaction holdings. Because the activity is tax-related and immaterial to overall ownership, it is typically viewed as routine rather than a directional signal on the company’s prospects.

Roivant Sciences (ROIV) – Comunicazione Form 4 (30 lug 2025)

Il CFO Richard Pulik ha riportato una cessione automatica di 1.919 azioni ordinarie il 28 lug 2025 a un prezzo implicito di 11,35 $. L’operazione è classificata come “F”, indicando che l’emittente ha trattenuto azioni per coprire le tasse dovute al momento della maturazione di unità azionarie vincolate (RSU) precedentemente assegnate; non si è verificata alcuna vendita sul mercato aperto. Dopo il regolamento netto, Pulik mantiene 397.553 azioni, pertanto le azioni cedute rappresentano circa lo 0,5% del suo patrimonio azionario dopo la transazione. Poiché l’operazione è legata a questioni fiscali e non ha un impatto significativo sulla proprietà complessiva, viene generalmente considerata routine piuttosto che un segnale indicativo delle prospettive dell’azienda.

Roivant Sciences (ROIV) – Presentación Formulario 4 (30 jul 2025)

El CFO Richard Pulik reportó una disposición automática de 1,919 acciones comunes el 28 de julio de 2025 a un precio implícito de $11.35. La transacción está codificada como “F”, lo que indica que el emisor retuvo acciones para cubrir impuestos adeudados tras la consolidación de unidades restringidas de acciones (RSU) previamente otorgadas; no hubo venta en el mercado abierto. Tras el ajuste neto, Pulik conserva 397,553 acciones, por lo que las acciones entregadas representan aproximadamente el 0.5 % de sus tenencias posteriores a la transacción. Dado que la actividad está relacionada con impuestos y no es significativa para la propiedad total, generalmente se considera rutinaria en lugar de una señal direccional sobre las perspectivas de la empresa.

로이벤트 사이언시스 (ROIV) – Form 4 신고 (2025년 7월 30일)

최고재무책임자(CFO) 리차드 풀릭은 2025년 7월 28일에 1,919주 보통주의 자동 처분을 보고했으며, 암시된 가격은 $11.35였습니다. 이 거래는 “F” 코드로 표시되었는데, 이는 발행사가 이전에 부여된 제한 주식 단위(RSU)의 권리 확정 시 발생하는 세금을 충당하기 위해 주식을 원천징수했음을 의미하며, 공개 시장에서의 매도는 없었습니다. 순결제 후 풀릭은 397,553주를 보유하고 있어, 포기한 주식은 거래 후 보유 주식의 약 0.5%에 해당합니다. 이 활동은 세금 관련이며 전체 소유권에 미치는 영향이 미미하므로 일반적으로 회사 전망에 대한 방향성 신호보다는 일상적인 것으로 간주됩니다.

Roivant Sciences (ROIV) – Déclaration Formulaire 4 (30 juillet 2025)

Le directeur financier Richard Pulik a déclaré une cession automatique de 1 919 actions ordinaires le 28 juillet 2025 à un prix implicite de 11,35 $. La transaction est codée « F », ce qui indique que l’émetteur a retenu des actions pour couvrir les taxes dues lors de l’acquisition de droits sur des unités d’actions restreintes (RSU) précédemment attribuées ; aucune vente sur le marché libre n’a eu lieu. Après le règlement net, Pulik conserve 397 553 actions, les actions cédées représentant environ 0,5 % de ses avoirs post-transaction. Étant donné que cette opération est liée à des obligations fiscales et qu’elle est sans impact significatif sur la propriété globale, elle est généralement considérée comme routinière plutôt que comme un signal directionnel sur les perspectives de l’entreprise.

Roivant Sciences (ROIV) – Form 4 Meldung (30. Juli 2025)

CFO Richard Pulik meldete am 28. Juli 2025 eine automatische Veräußerung von 1.919 Stammaktien zu einem impliziten Preis von 11,35 $. Die Transaktion ist mit „F“ codiert, was darauf hinweist, dass der Emittent Aktien einbehalten hat, um die bei der Vesting von zuvor gewährten Restricted Stock Units (RSUs) fälligen Steuern zu begleichen; ein Verkauf am offenen Markt fand nicht statt. Nach der Nettoregelung hält Pulik 397.553 Aktien, sodass die abgegebenen Aktien etwa 0,5 % seines Bestands nach der Transaktion entsprechen. Da die Aktivität steuerbedingt ist und keine wesentliche Auswirkung auf die Gesamtbeteiligung hat, wird sie üblicherweise als routine und nicht als richtungsweisendes Signal für die Unternehmensperspektiven betrachtet.

Positive
  • RSU vesting signals continued employment of the CFO and ongoing equity-based alignment with shareholders.
  • Large residual holding (≈397k shares) maintains significant insider skin-in-the-game.
Negative
  • Minor share count reduction technically increases float, though effect is immaterial.
  • Investors who focus only on headline 'insider sale' may misinterpret the filing as bearish.

Insights

TL;DR: Routine tax withholding; negligible ownership change—neutral signal.

The F-code confirms shares were withheld by Roivant to satisfy Pulik’s tax obligation as RSUs vested. Only 1,919 shares (≈$22 k) were removed versus nearly 400 k still owned, leaving the CFO’s economic exposure intact. No derivative transactions were listed, and there is no evidence of discretionary selling. Such filings rarely influence valuation or liquidity given the de-minimis size and non-volitional nature. Overall impact on share-price sentiment is neutral.

Roivant Sciences (ROIV) – Comunicazione Form 4 (30 lug 2025)

Il CFO Richard Pulik ha riportato una cessione automatica di 1.919 azioni ordinarie il 28 lug 2025 a un prezzo implicito di 11,35 $. L’operazione è classificata come “F”, indicando che l’emittente ha trattenuto azioni per coprire le tasse dovute al momento della maturazione di unità azionarie vincolate (RSU) precedentemente assegnate; non si è verificata alcuna vendita sul mercato aperto. Dopo il regolamento netto, Pulik mantiene 397.553 azioni, pertanto le azioni cedute rappresentano circa lo 0,5% del suo patrimonio azionario dopo la transazione. Poiché l’operazione è legata a questioni fiscali e non ha un impatto significativo sulla proprietà complessiva, viene generalmente considerata routine piuttosto che un segnale indicativo delle prospettive dell’azienda.

Roivant Sciences (ROIV) – Presentación Formulario 4 (30 jul 2025)

El CFO Richard Pulik reportó una disposición automática de 1,919 acciones comunes el 28 de julio de 2025 a un precio implícito de $11.35. La transacción está codificada como “F”, lo que indica que el emisor retuvo acciones para cubrir impuestos adeudados tras la consolidación de unidades restringidas de acciones (RSU) previamente otorgadas; no hubo venta en el mercado abierto. Tras el ajuste neto, Pulik conserva 397,553 acciones, por lo que las acciones entregadas representan aproximadamente el 0.5 % de sus tenencias posteriores a la transacción. Dado que la actividad está relacionada con impuestos y no es significativa para la propiedad total, generalmente se considera rutinaria en lugar de una señal direccional sobre las perspectivas de la empresa.

로이벤트 사이언시스 (ROIV) – Form 4 신고 (2025년 7월 30일)

최고재무책임자(CFO) 리차드 풀릭은 2025년 7월 28일에 1,919주 보통주의 자동 처분을 보고했으며, 암시된 가격은 $11.35였습니다. 이 거래는 “F” 코드로 표시되었는데, 이는 발행사가 이전에 부여된 제한 주식 단위(RSU)의 권리 확정 시 발생하는 세금을 충당하기 위해 주식을 원천징수했음을 의미하며, 공개 시장에서의 매도는 없었습니다. 순결제 후 풀릭은 397,553주를 보유하고 있어, 포기한 주식은 거래 후 보유 주식의 약 0.5%에 해당합니다. 이 활동은 세금 관련이며 전체 소유권에 미치는 영향이 미미하므로 일반적으로 회사 전망에 대한 방향성 신호보다는 일상적인 것으로 간주됩니다.

Roivant Sciences (ROIV) – Déclaration Formulaire 4 (30 juillet 2025)

Le directeur financier Richard Pulik a déclaré une cession automatique de 1 919 actions ordinaires le 28 juillet 2025 à un prix implicite de 11,35 $. La transaction est codée « F », ce qui indique que l’émetteur a retenu des actions pour couvrir les taxes dues lors de l’acquisition de droits sur des unités d’actions restreintes (RSU) précédemment attribuées ; aucune vente sur le marché libre n’a eu lieu. Après le règlement net, Pulik conserve 397 553 actions, les actions cédées représentant environ 0,5 % de ses avoirs post-transaction. Étant donné que cette opération est liée à des obligations fiscales et qu’elle est sans impact significatif sur la propriété globale, elle est généralement considérée comme routinière plutôt que comme un signal directionnel sur les perspectives de l’entreprise.

Roivant Sciences (ROIV) – Form 4 Meldung (30. Juli 2025)

CFO Richard Pulik meldete am 28. Juli 2025 eine automatische Veräußerung von 1.919 Stammaktien zu einem impliziten Preis von 11,35 $. Die Transaktion ist mit „F“ codiert, was darauf hinweist, dass der Emittent Aktien einbehalten hat, um die bei der Vesting von zuvor gewährten Restricted Stock Units (RSUs) fälligen Steuern zu begleichen; ein Verkauf am offenen Markt fand nicht statt. Nach der Nettoregelung hält Pulik 397.553 Aktien, sodass die abgegebenen Aktien etwa 0,5 % seines Bestands nach der Transaktion entsprechen. Da die Aktivität steuerbedingt ist und keine wesentliche Auswirkung auf die Gesamtbeteiligung hat, wird sie üblicherweise als routine und nicht als richtungsweisendes Signal für die Unternehmensperspektiven betrachtet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pulik Richard

(Last) (First) (Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY

(Street)
LONDON X0 SW1H 0DB

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 07/28/2025 F 1,919(1) D $11.35 397,553 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik 07/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Roivant (ROIV) shares did CFO Richard Pulik dispose of?

He surrendered 1,919 common shares on 28 Jul 2025.

What was the transaction code in the July 2025 Form 4 for ROIV?

The filing lists transaction code F, meaning shares were withheld for tax purposes on RSU vesting.

What is Richard Pulik's remaining ownership in ROIV after the filing?

Pulik now beneficially owns 397,553 common shares directly.

Did the CFO sell shares on the open market?

No. The shares were net-settled by the issuer for withholding taxes; no open-market sale occurred.

Is the Form 4 transaction likely to impact Roivant’s stock price?

Given the small size (≈0.5 % of holdings) and tax-related nature, analysts view the impact as negligible.
Roivant Sciences

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Latest SEC Filings

ROIV Stock Data

7.76B
399.33M
27.66%
80.12%
6.47%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON